Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| PTC Therapeutics Inc | PTCT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 36.36 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 36.36 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 17.53 - 45.68 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 36.36 | USD |
PTC Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.79B | 76.61M | - | 1.07B | -626.6M | -8.18 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
PTC Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTCT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 37.575 | 37.755 | 34.80 | 35.87 | 772,578 | -1.22 | -3.23% |
| 1 Month | 32.96 | 40.69 | 30.705 | 35.76 | 841,345 | 3.40 | 10.32% |
| 3 Months | 31.19 | 40.69 | 23.995 | 30.84 | 887,667 | 5.17 | 16.58% |
| 6 Months | 24.08 | 40.69 | 23.58 | 28.92 | 994,731 | 12.28 | 51.00% |
| 1 Year | 43.83 | 45.68 | 17.53 | 28.68 | 1,033,441 | -7.47 | -17.04% |
| 3 Years | 38.57 | 59.84 | 17.53 | 36.37 | 773,700 | -2.21 | -5.73% |
| 5 Years | 40.10 | 70.82 | 17.53 | 40.83 | 721,745 | -3.74 | -9.33% |
PTC Therapeutics Description
| PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
